Vir Biotechnology (VIR) Retained Earnings (2018 - 2026)

Vir Biotechnology has reported Retained Earnings for 9 years, with the latest figure at -$1.3 billion in Q1 2026.

• Quarterly Retained Earnings fell 50.27% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 50.27% YoY) and the FY2025 annual result came in at -$1.2 billion, down 69659.52% from the prior year.
• Retained Earnings retreated to -$1.3 billion in Q1 2026 per VIR's latest filing, from -$1.2 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $1.9 billion in Q1 2024 and troughed at -$1.3 billion in Q1 2026.
• A 5-year average of $110.0 million and a median of -$3.2 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 57659.46% in 2024, then plunged 69659.52% in 2025.
• Over 5 years, Retained Earnings stood at $1.7 billion in 2022, then climbed by 6.96% to $1.8 billion in 2023, then sank by 100.09% to -$1.7 million in 2024, then slumped by 69659.52% to -$1.2 billion in 2025, then fell by 10.49% to -$1.3 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$1.3 billion, -$1.2 billion, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.